**Ovary, Fallopian Tube and Primary Peritoneal Carcinoma Reporting Proforma**

Includes the International Collaboration on Cancer Reporting dataset elements denoted by *.  

<table>
<thead>
<tr>
<th>Field</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Family name</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Given name(s)</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Date of birth</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Date of request</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Ethnicity</strong></td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td></td>
</tr>
<tr>
<td>Aboriginal/Torres Strait Islander</td>
<td></td>
</tr>
<tr>
<td>Other ethnicity:</td>
<td></td>
</tr>
<tr>
<td><strong>Patient identifiers</strong></td>
<td></td>
</tr>
<tr>
<td>e.g. MRN, IHI or NHI (please indicate which)</td>
<td></td>
</tr>
<tr>
<td><strong>Date of request</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Accession number</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Requests doctor - name and contact details</strong></td>
<td></td>
</tr>
</tbody>
</table>

**Clinical information**

*GENETIC STATUS*
- Not known
- BRCA1
- BRCA2
- Lynch syndrome
- Other

*PRIOR CHEMOTHERAPY*
- Not known
- No chemotherapy administered
- Prior chemotherapy administered

**PREVIOUS GYNAE. PROCEDURE OR TREATMENT**

**OPERATIVE PROCEDURE**
- Left oophorectomy
- Right oophorectomy
- Left salpingo-oophorectomy
- Right salpingo-oophorectomy
- Left salpingectomy
- Right salpingectomy
- Peritoneal resection
- Omentectomy
- Total hysterectomy with bilateral salpingo-oophorectomy
- Other (specify)

**NEW PRIMARY TUMOUR OR RECURRENCE**
- New primary
- Regional (local) recurrence
- Distant metastases

**S1.04 PRINCIPAL CLINICIAN**

**S1.01 OTHER CLINICAL INFORMATION RECEIVED**
**Macroscopic findings**

**S2.02** SPECIMEN LABELLED AS

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**S2.03** SPECIMEN TYPE (select all that apply)

- Right ovary
- Left ovary
- Right ovarian cystectomy
- Left ovarian cystectomy
- Right fallopian tube
- Left fallopian tube
- Uterus
- Cervix
- Omentum
- Peritoneal biopsies
- Peritoneal washings/ascitic fluid
- Lymph nodes (specify site/s)
- Other eg bowel, bladder, appendix (specify)

For each specimen received, record S2.04-6 and consider recording G2.01-6 as applicable.

**RIGHT OVARY**

**S2.04** SPECIMEN INTEGRITY

- Ovarian capsule intact
- Ovarian capsule ruptured
- Tumour on surface
- Fragmented specimen
- Other

**G2.01** SPECIMEN WEIGHT

Note: This will primarily be the ovary/adnexal mass weight

**G2.02** DIMENSIONS

- length mm x width mm x thickness mm

**DESCRIPTION**

**G2.03** TUMOUR DIMENSIONS

Note: If separate tumours specify dimensions for each. Record only if tumour present macroscopically

- Tumour 1
  - length mm x width mm x thickness mm
- Tumour 2
  - length mm x width mm x thickness mm

**G2.04** TUMOUR DESCRIPTION(S)

Note: Record only if tumour present

**LEFT OVARY**

**S2.04** SPECIMEN INTEGRITY

Required only if ovary(ies) are submitted

- Ovarian capsule intact
- Ovarian capsule ruptured
- Tumour on surface
- Fragmented specimen
- Other

**G2.01** SPECIMEN WEIGHT

Note: This will primarily be the ovary/adnexal mass weight

**G2.02** DIMENSIONS

- length mm x width mm x thickness mm

**DESCRIPTION**

**G2.03** TUMOUR DIMENSIONS

Note: If separate tumours specify dimensions for each. Record only if tumour present macroscopically

- Tumour 1
  - length mm x width mm x thickness mm
- Tumour 2
  - length mm x width mm x thickness mm

**G2.04** TUMOUR DESCRIPTION(S)

Record only if tumour present macroscopically

**RIGHT FALLOPIAN TUBE**

**S2.04** SPECIMEN INTEGRITY

Required only if fallopian tube(s) are submitted

- Serosa intact
- Serosa ruptured
- Tumour on serosal surface
- Fragmented specimen
- Other

**G2.03** TUMOUR DIMENSIONS

Note: If separate tumours specify dimensions for each. Record only if tumour present macroscopically

- Tumour 1
  - length mm x width mm x thickness mm
- Tumour 2
  - length mm x width mm x thickness mm

**G2.04** TUMOUR DESCRIPTION(S)

Record only if tumour present macroscopically

**Vers. 1.0 Proforma for Ovary, Fallopian Tube and Primary Peritoneal Carcinoma Protocol 1st Edition**
G2.02 **DIMENSIONS**  
Note: 2 dimensions (length x diameter) should be recorded as a minimum, if abnormal, a third dimension should be recorded.

| mm | mm | mm |

FIMBRIAE
Not identified  ○  
Present  ○

**DESCRIPTION**

---

G2.03 **TUMOUR DIMENSIONS**  
Note: If separate tumours specify dimensions for each. Record only if tumour present macroscopically.

Tumour 1

| length mm | width mm | thickness mm |

Tumour 2

| length mm | width mm | thickness mm |

---

G2.04 **TUMOUR DESCRIPTION(S)**  
Record only if tumour present macroscopically

---

**LEFT FALLOPIAN TUBE**

G2.04 **SPECIMEN INTEGRITY**  
Required only if fallopian tube(s) are submitted

- □ Serosa intact
- □ Serosa ruptured
- □ Tumour on serosal surface
- □ Fragmented specimen
- □ Other

**DESCRIPTION**

---

G2.02 **DIMENSIONS**  
Note: 2 dimensions (length x diameter) should be recorded as a minimum, if abnormal, a third dimension should be recorded.

| mm | mm | mm |

FIMBRIAE
Not identified  ○  
Present  ○

**DESCRIPTION**

---

**UTERUS**

G2.01 **SPECIMEN WEIGHT**  
Note: This will primarily be the ovary/adnexal mass weight

\[ g \]

State what is included...

---

G2.02 **DIMENSIONS**  
Note: superior to inferior x distance between cornu x anterior to posterior

| mm | mm | mm |

**DESCRIPTION**

---

G2.03 **TUMOUR DIMENSIONS**  
Note: If separate tumours specify dimensions for each. Record only if tumour present macroscopically.

Tumour 1

| length mm | width mm | thickness mm |

Tumour 2

| length mm | width mm | thickness mm |

---

G2.04 **TUMOUR DESCRIPTION(S)**  
Record only if tumour present macroscopically

---

**OTHER SPECIMEN(S)**

---
**S2.05  MACRO. DESCRIPTION OF OMENTUM**

*Note: Required only if omentum submitted*

**Omentum dimensions**

<p>| | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>mm x</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>mm x</td>
</tr>
</tbody>
</table>

**Omental involvement**

Involved □  Not involved ○

**Max. dimension of largest deposit**

<p>| |</p>
<table>
<thead>
<tr>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>mm</td>
</tr>
</tbody>
</table>

G2.05  Number of metastatic deposits

<p>| |</p>
<table>
<thead>
<tr>
<th></th>
</tr>
</thead>
</table>

**Size of metastatic deposits**

<table>
<thead>
<tr>
<th>mm</th>
<th>mm</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**S2.06  MACROSCOPIC TUMOUR SITE**

*Note: Required only if not previously reported in G2.02. Select all that apply*

- □ Left ovary
- □ Right ovary
- □ Left fallopian tube
  - □ Fimbrial
  - □ Non fimbrial
- □ Right fallopian tube
  - □ Fimbrial
  - □ Non fimbrial
- □ Peritoneum
- □ Other (specify)
- ○ Indeterminate

G2.06  LYMPH NODES (describe)

<p>| |</p>
<table>
<thead>
<tr>
<th></th>
</tr>
</thead>
</table>

**S2.07  BLOCK IDENTIFICATION KEY**

<p>| |</p>
<table>
<thead>
<tr>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

**S2.08  OTHER MACROSCOPIC DESCRIPTION**

<p>| |</p>
<table>
<thead>
<tr>
<th></th>
</tr>
</thead>
</table>

**Microscopic findings**

**S3.01  HISTOLOGICAL TUMOUR TYPE**

- □ Epithelial
  - Percentage %
  - List subtypes

- □ Sarcomatous
  - Percentage %
  - Type
    - ○ Homologous
    - □ Heterologous
    - List subtypes

**S3.02  TUMOUR GRADE**

*Note: If chemotherapy has been administered the grading may need to be based on the pre-chemotherapy biopsy.*

- Serous carcinomas:
  - ○ Low grade
  - ○ Cannot be graded
  - High grade

- Endometrioid carcinomas:
  - ○ G1: Well differentiated
  - ○ G2: Moderately
  - ○ G3: Poorly differentiated
  - ○ GX: Cannot be graded

- Clear cell carcinomas:
  - ○ High grade

- Undifferentiated carcinomas:
  - ○ High grade

- Carcinosarcomas:
  - ○ High grade
G3.03  *Mucinous carcinomas:
- G1: Well differentiated
- G2: Moderately differentiated
- G3: Poorly differentiated
- GX: Cannot be graded

G3.04  *Nodules of anaplastic carcinoma
Note: For mucinous tumours only
- Not identified
- Present

S3.03  *BORDERLINE TUMOUR
- Present
- Absent

S3.04  *HISTOLOGICAL TUMOUR TYPE

S3.05  *SPECIAL FEATURES
Micropapillary architecture for serous borderline tumour
Note: at least 5 mm in one dimension
- Absent
- Present
Microinvasion
Note: upper limit 5 mm
- Absent
- Present

S3.06  *IMPLANTS FOR SEROUS & SEROMUCINOUS BORDERLINE TUMOUR
Note: Applicable to serous and seromucinous borderline tumours only.
Non-invasive implants
- Present
- Not identified
- Epithelial
- Desmoplastic
Site(s):
- Pelvic
- Abdominal

Invasive implants/Extra-ovarian low grade serous carcinoma
- Present
- Not identified
Site(s):
- Pelvic
- Abdominal
Indeterminate
- Present
- Not identified
Site(s):
- Pelvic
- Abdominal

G3.06  Size of the largest implant

S3.07  *SEROUS TUBAL INTRAEPITHELIAL CARCINOMA (STIC)
Note: Required only if fallopian tube(s) are submitted and applicable to high grade serous carcinoma only
Right FT
- Present - fimbrial
- Present - non-fimbrial
- Not identified
- Cannot be assessed
Left FT
- Present - fimbrial
- Present - non-fimbrial
- Not identified
- Cannot be assessed

G3.07  OTHER SIGNIFICANT TUBAL LESIONS

G3.08  HISTOLOGICAL FEATURES

S3.08  *HISTOLOGICAL SITES OF TUMOUR INVOLVEMENT

Right ovary
- Not involved
- Involved
- Cannot be assessed
- Not applicable

Left ovary
- Not involved
- Involved
- Cannot be assessed
- Not applicable

Right ovarian capsule/surface
- Not involved
- Involved
- Cannot be assessed
- Not applicable

Left ovarian capsule/surface
- Not involved
- Involved
- Cannot be assessed
- Not applicable

Right fallopian tube
- Not involved
- Involved
- Cannot be assessed
- Not applicable

Left fallopian tube
- Not involved
- Involved
- Cannot be assessed
- Not applicable

Uterus (Note: for peritoneal involvement refer to Peritoneum (including uterine serosa) below)
- Not involved
- Involved
- Cannot be assessed
- Not applicable
Site(s):
- Myometrium
- Endometrium
- Cervix
Omentum
- Not involved
- Involved

Level of involvement:
- Macroscopic
- Microscopic

Peritoneum (including uterine serosa)
- Not involved
- Involved

Site(s):
- Pelvis (specify site(s), including uterine serosa)
- Abdomen (specify site(s))

Other involved organs(s)/sites(s) (specify)

SITE OF TUBAL INVOLVEMENT
- Indeterminate
- Fimbrial
- Non-fimbrial

LYMPHOVASCULAR INVASION
- Not identified
- Present

LYMPH NODE STATUS
- Not submitted
- Not involved
- Involved

Regional
- Left pelvic
- Right pelvic
- Para-aortic

Number of lymph nodes examined**
Number of positive lymph nodes**

Maximum dimension of largest deposit in regional node

Site/Number of LN examined and Number of positive LN as needed.

PERITONEAL CYTOLOGY
- Negative
- Positive
- Indeterminate
- Not received

RESPONSE TO NEOADJUVANT THERAPY
- No prior treatment
- Cannot be assessed

COEXISTENT PATHOLOGY
- Endometriosis (specify sites)
- Other (specify)

OPTIMAL TUMOUR BLOCK(S)

ADDITIONAL MICROSCOPIC COMMENT

Note: Repeat "Site/Number of LN examined and Number of positive LN as needed."
Ancillary test findings

G4.02 IMMUNOHISTOCHEMICAL MARKERS

G4.03 MOLECULAR DATA

G4.01 OTHER ANCILLARY FINDINGS

Synthesis and overview

G5.02 DIAGNOSTIC SUMMARY
Include: Primary tumour site; Histological type; Tumour grade; Ovarian surface involvement, if applicable; Dimension of largest omental deposit, if applicable; Involvement of other tissue/organisms if present; Peritoneal cytology status; Lymph node status; In cases of borderline tumour document implants and type if present.

G5.01 FIGO STAGE (2014 edition) (Copyright permission pending)
Site of primary tumour
- Primary tumour, ovary (OV)
- Primary tumour, fallopian tube (FT)
- Primary tumour, peritoneum (P)
- Undesignated: site of primary tumour cannot be assessed (X)

Stage
- I Tumour is confined to ovaries or fallopian tube(s)
  - IA Tumour limited to 1 ovary (capsule intact) or fallopian tube; no tumor on ovarian or fallopian tube surface; no malignant cells in the ascites or peritoneal washings
  - IB Tumour limited to both ovaries (capsules intact) or fallopian tubes; no tumour on ovarian or fallopian tube surface; no malignant cells in the ascites or peritoneal washings
  - IC Tumour limited to 1 or both ovaries or fallopian tubes, with any of the following:
    - IC1 Surgical spill
    - IC2 Capsule ruptured before surgery or tumour on ovarian or fallopian tube surface
    - IC3 Malignant cells in the ascites or peritoneal washings
- II Tumour involves 1 or both ovaries or fallopian tubes with pelvic extension (below pelvic brim) or primary peritoneal cancer
  - IIA Extension and/or implants on uterus and/or fallopian tubes and/or ovaries
  - IIB Extension to other pelvic intraperitoneal tissues
- III Tumour involves 1 or both ovaries or fallopian tubes, or primary peritoneal cancer, with cytologically or histologically confirmed spread to the peritoneum outside the pelvis and/or metastasis to the retroperitoneal lymph nodes
  - IIIA1 Positive retroperitoneal lymph nodes only (cytologically or histologically proven):
    - IIIA1(i) Metastasis up to 10mm in greatest dimension
    - IIIA1(ii) Metastasis more than 10mm in greatest dimension
  - IIIA2 Microscopic extrapelvic (above the pelvic brim) peritoneal involvement with or without positive retroperitoneal lymph nodes
- IIIB Macroscopic peritoneal metastasis beyond the pelvis up to 2cm in greatest dimension, with or without metastasis to the retroperitoneal lymph nodes
- IIIC Macroscopic peritoneal metastasis beyond the pelvis more than 2cm in greatest dimension, with or without metastasis to the retroperitoneal lymph nodes (includes extension of tumor to capsule of liver and spleen without parenchymal involvement of either organ)
- IV Distant metastasis excluding peritoneal metastases
  - IVA Pleural effusion with positive cytology
  - IVB Parenchymal metastases and metastases to extra-abdominal organs (including inguinal lymph nodes and lymph nodes outside of the abdominal cavity)

G5.03 EDITION/VERSION NUMBER OF THE RCPA PROTOCOL ON WHICH THE REPORT IS BASED
Ovary, Fallopian Tube and Primary Peritoneal Site Carcinoma Structured Reporting Protocol (1st Edition 2016)

S5.01 Year of publication and edition of cancer staging system, if included

Note: If appropriate, highlight the need for further assessment, eg genetic testing or family cancer clinic referral.